Demonstrated hormetic mechanisms putatively subserve riluzole-induced effects in neuroprotection against amyotrophic lateral sclerosis (ALS): Implications for research and clinical practice |
| |
| Affiliation: | 1. Shock Trauma and Anesthesiology Research Center, University of MD School of Medicine, USA;2. Department of Neurology, The First Teaching Hospital, Jilin University, China;1. Neural Injury Research Center, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, Republic of Korea;2. Department of Ophthalmology, University of Ulsan College of Medicine, Seoul, Republic of Korea;3. Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;4. Department of Bioscience and Biotechnology, Sejong University, Seoul, Republic of Korea;1. Department of Environmental Health Sciences, University of Massachusetts, Amherst, MA, United States;2. Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States;3. Human Research Protection Office, Research Compliance, University of Massachusetts, Hadley, MA, United States;4. Saint Francis Hospital and Medical Center Hartford, Hartford, CT, United States;5. Department of Biomedical & Biotechnological Sciences, School of Medicine, University of Catania, Catania, Italy;6. Departments of Neurology & Biochemistry, Georgetown University Medical Center, Washington, DC, United States |
| |
| Abstract: | This paper provides evidence to support that riluzole, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS), like many neuroprotective agents, displays and exerts hormetic biphasic dose responses. These findings have important implications for the experimental study and clinical treatment of ALS. |
| |
| Keywords: | ALS Riluzole Hormesis Neuroprotection Dose response Acquired resilience |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
